Primary aldosteronism patient prognosis evaluation method and device

Abstract

The invention relates to a primary aldosteronism patient prognosis evaluation method and device, and the method comprises the steps: obtaining the basic information of a patient; measuring blood pressure information of the patient to obtain systolic pressure of the patient; collecting a blood sample of the patient, and determining a prognosis indication parameter value of the patient from the blood sample of the patient; taking the basic information, the systolic pressure and the prognosis indication parameter value of the patient as input of a prognosis evaluation model to obtain a prognosis evaluation score; and determining a prognosis evaluation result of the patient according to the interval of the prognosis evaluation score. According to the invention, quantitative prognosis evaluation can be realized.

Description

Technical Field

[0001] The present invention relates to an intelligent medical technology system, and in particular to a method and device for evaluating the prognosis of patients with primary aldosteronism. Background Art

[0002] Primary aldosteronism is one of the common causes of secondary hypertension. Its prevalence in patients with refractory hypertension in my country is 11%-29%, and its incidence in newly diagnosed hypertensive patients is 5%-15%. Primary aldosteronism is caused by the autonomous secretion of aldosterone by the adrenal glands, which inhibits the activity of the renin-angiotensin system in the body. The main clinical manifestations are hypertension and hypokalemia. Distinguishing between unilateral and bilateral primary aldosteronism is of great significance for treatment. Unilateral primary aldosteronism can be treated surgically, and the patient's blood pressure and hypokalemia can be improved to a certain extent or even completely restored to normal after treatment. However, bilateral primary aldosteronism lesions are mainly treated with drugs, and the prognosis is relatively poor.

[0003] Currently, the prognosis evaluation of primary aldosteronism is based on the clinical efficacy evaluation of the industry standard for the diagnosis and treatment of primary aldosteronism. This standard does not provide a quantitative prognosis evaluation method, and it must rely on professional medical institutions for evaluation, which makes the prognosis evaluation inefficient and slow. Summary of the invention

[0004] The technical problem to be solved by the present invention is to provide a method and device for evaluating the prognosis of patients with primary aldosteronism, which can realize quantitative prognosis evaluation.

[0005] The technical solution adopted by the present invention to solve the technical problem is: to provide a method for evaluating the prognosis of patients with primary aldosteronism, comprising the following steps:

[0006] Obtain basic information about the patient;

[0007] Measure the patient's blood pressure information to obtain the patient's systolic blood pressure;

[0008] Collecting blood samples from patients, and determining the values ​​of prognostic indicator parameters of patients from the blood samples;

[0009] The patient's basic information, systolic blood pressure, and prognostic indicator parameter values ​​are used as inputs to the prognostic evaluation model to obtain a prognostic evaluation score;

[0010] The prognosis evaluation result of the patient is determined according to the interval in which the prognosis evaluation score lies.

[0011] Before collecting the patient's blood sample, the patient should stop taking mineralocorticoid receptor antagonists and non-potassium-sparing diuretics for 4 weeks, and stop taking β-blockers, angiotensin-converting enzyme inhibitors, and angiotensin II receptor blockers for 2 weeks; replace antihypertensive drugs with non-dihydropyridine calcium blockers and / or α-blockers.

[0012] When collecting the patient's blood sample, the patient should maintain an upright position for a first preset duration, sit down for a second preset duration after the first preset duration, and have the blood sample collected after the second preset duration; the time period for collecting the blood sample is in the morning; among them, the first preset duration is 8 times the second preset duration.

[0013] The patient's basic information includes: age, gender, KCNJ5 gene mutation, hypertension duration, and body mass index; the prognostic indicator parameter values include: cortisol and renin activity.

[0014] The prognostic assessment model is: Among them, S is the prognostic assessment score, A is the patient's age, B represents the patient's gender, when the gender is male, B = 1, when the gender is female, B = 2; C is the KCNJ5 gene mutation, when the KCNJ5 gene has a mutation, C = 2, when the KCNJ5 gene has no mutation, C = 1; D is the hypertension duration; E is the patient's body mass index; F is the patient's systolic blood pressure; G is the patient's cortisol; H is the patient's renin activity.

[0015] Determine the patient's prognostic assessment result according to the interval where the prognostic assessment score is located. Specifically:

[0016] When the prognostic assessment score is: S > -1.510, the possibility of the patient having a complete clinical remission after surgery is less than 20%;

[0017] When the prognostic assessment score is: -1.163 < S ≤ -1.510, the possibility of the patient having a complete clinical remission after surgery is 73%;

[0018] When the prognostic assessment score is: -0.462 < S ≤ -1.163, the possibility of the patient having a complete clinical remission after surgery is 75%;

[0019] When the prognostic assessment score is: -0.462 < S ≤ -0.207, the possibility of the patient having a complete clinical remission after surgery is 80%;

[0020] When the prognostic assessment score is: S < -0.207, the possibility of the patient having a complete clinical remission after surgery is 90%.

[0021] Among them, S is the prognostic assessment score.

[0022] The technical solution adopted by the present invention to solve the technical problem is: to provide a device for evaluating the prognosis of patients with primary aldosteronism, comprising:

[0023] Acquisition module, used to obtain basic information of patients;

[0024] A blood pressure measurement module is used to measure the patient's blood pressure information and obtain the patient's systolic blood pressure;

[0025] A blood sample collection module is used to collect blood samples from patients and determine the patient's prognostic indicator parameter value from the patient's blood samples;

[0026] An evaluation module is used to use the patient's basic information, systolic blood pressure and prognostic indicator parameter values ​​as inputs to the prognostic evaluation model to obtain a prognostic evaluation score;

[0027] The determination module is used to determine the patient's prognosis evaluation result according to the interval in which the prognosis evaluation score lies.

[0028] The basic information of the patient includes: age, gender, KCNJ5 gene mutation, course of hypertension and body mass index; the prognostic indicator parameter values ​​include: cortisol and renin activity.

[0029] The prognostic evaluation model is: Among them, S is the prognostic assessment score, A is the patient's age, B represents the patient's gender, when the gender is male, B=1, when the gender is female, B=2; C is the KCNJ5 gene mutation, when the KCNJ5 gene has a mutation, C=2, when the KCNJ5 gene has no mutation, C=1; D is the course of hypertension; E is the patient's body mass index; F is the patient's systolic blood pressure; G is the patient's cortisol; H is the patient's renin activity.

[0030] The technical solution adopted by the present invention to solve its technical problem is: providing a computer-readable storage medium on which a computer program is stored, and when the computer program is executed by a processor, the steps of the above-mentioned method for evaluating the prognosis of patients with primary aldosteronism are implemented.

[0031] Beneficial Effects

[0032] Due to the adoption of the above technical solution, the present invention has the following advantages and positive effects compared with the prior art: the present invention can quickly obtain an evaluation conclusion based on the patient's prognostic indicator parameter value combined with the prognostic evaluation model, and can obtain a specific quantitative score based on the prognostic evaluation model, and can obtain an accurate quantitative conclusion based on the score. In addition, the method of the present invention can be made into a software application and installed in the patient's terminal, and the patient can fill in the information for evaluation by himself without relying on professional medical institutions. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Figure 1 It is a flowchart of a method for evaluating the prognosis of a patient with primary aldosteronism according to a first embodiment of the present invention. DETAILED DESCRIPTION

[0034] The present invention will be further described below in conjunction with specific embodiments. It should be understood that these embodiments are only used to illustrate the present invention and are not intended to limit the scope of the present invention. In addition, it should be understood that after reading the content taught by the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms fall within the scope limited by the appended claims of the application equally.

[0035] The first embodiment of the present invention relates to a method for evaluating the prognosis of a patient with primary aldosteronism, such as Figure 1 As shown, the following steps are included:

[0036] Step 1, obtaining the basic information of the patient; wherein the basic information includes: age, gender, KCNJ5 gene mutation, course of hypertension and body mass index.

[0037] Step 2: Measure the patient's blood pressure information to obtain the patient's systolic blood pressure.

[0038] Step 3, collecting blood samples from patients, and determining the patient's prognostic indicator parameter value from the patient's blood samples.

[0039] Before this step, the patient needs to stop using mineralocorticoid receptor antagonists and non-potassium-sparing diuretics for 4 weeks, and stop using beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensin II receptor blockers for 2 weeks; replace antihypertensive drugs with non-dihydropyridine calcium blockers and / or alpha-blockers. When collecting blood samples from patients, the time period for blood sampling is in the morning. The patient needs to maintain an upright position for 2 hours, then sit down for 15 minutes, and then the blood sample is collected. Among them, the blood sample needs to be kept in an ice bath during the inspection process, and the plasma is frozen and stored immediately after centrifugation.

[0040] Step 4: The patient's basic information, systolic blood pressure and prognostic indicator parameter values ​​are used as inputs to the prognostic evaluation model to obtain a prognostic evaluation score. In this step, the prognostic evaluation model is: Among them, S is the prognostic assessment score, A is the patient's age, B represents the patient's gender, when the gender is male, B=1, when the gender is female, B=2; C is the KCNJ5 gene mutation, when the KCNJ5 gene has a mutation, C=2, when the KCNJ5 gene has no mutation, C=1; D is the course of hypertension; E is the patient's body mass index; F is the patient's systolic blood pressure; G is the patient's cortisol; H is the patient's renin activity.

[0041] Step 5: Determine the prognosis evaluation result of the patient according to the interval where the prognosis evaluation score is located. Specifically: when the prognosis evaluation score is S > -1.510, the possibility of complete clinical remission after the patient's surgery is less than 20%; when the prognosis evaluation score is -1.163 < S ≤ -1.510, the possibility of complete clinical remission after the patient's surgery is 73%; when the prognosis evaluation score is -0.462 < S ≤ -1.163, the possibility of complete clinical remission after the patient's surgery is 75%; when the prognosis evaluation score is -0.462 < S ≤ -0.207, the possibility of complete clinical remission after the patient's surgery is 80%; when the prognosis evaluation score is S < -0.207, the possibility of complete clinical remission after the patient's surgery is 90%.

[0042] It is not difficult to find that based on the prognostic indication parameter values of the patient and combined with the prognosis evaluation model, the present invention can quickly obtain the evaluation conclusion, and using this prognosis evaluation model can obtain specific quantitative scores, and accurate quantitative conclusions can be obtained based on these scores. In addition, the method of the present invention can be made into a software application and installed in the patient's terminal, and the patient can fill in the information by himself for evaluation without relying on professional medical institutions.

[0043] The second embodiment of the present invention relates to a prognosis evaluation device for patients with primary aldosteronism, including:

[0044] An acquisition module for acquiring the basic information of the patient;

[0045] A blood pressure measurement module for measuring the blood pressure information of the patient to obtain the systolic blood pressure of the patient;

[0046] A blood sample collection module for collecting the blood sample of the patient and measuring the prognostic indication parameter value of the patient from the blood sample of the patient;

[0047] An evaluation module for taking the basic information, systolic blood pressure and prognostic indication parameter value of the patient as the input of the prognosis evaluation model to obtain the prognosis evaluation score;

[0048] A determination module for determining the prognosis evaluation result of the patient according to the interval where the prognosis evaluation score is located.

[0049] Before the blood sample collection module collects the blood sample of the patient, the patient needs to stop using mineralocorticoid receptor antagonists and non-potassium-sparing diuretics for 4 weeks, and stop using β-blockers, angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for 2 weeks; replace the antihypertensive drugs with non-dihydropyridine calcium blockers and / or α-blockers.

[0050] When the blood sample collection module collects the blood sample of the patient, the patient needs to maintain an upright posture within the first preset duration, sit down after the first preset duration and continue for the second preset duration, and collect the blood sample after the second preset duration; the time period for collecting the blood sample is in the morning; wherein, the first preset duration is 8 times the second preset duration.

[0051] The basic information of the patient includes: age, gender, KCNJ5 gene mutation, duration of hypertension, and body mass index; the prognostic index parameter values include: cortisol and renin activity.

[0052] The prognostic evaluation model adopted by the evaluation module is: Among them, S is the prognostic evaluation score, A is the age of the patient, B represents the gender of the patient. When the gender is male, B = 1; when the gender is female, B = 2; C is the KCNJ5 gene mutation. When there is a mutation in the KCNJ5 gene, C = 2; when there is no mutation in the KCNJ5 gene, C = 1; D is the duration of hypertension; E is the body mass index of the patient; F is the systolic blood pressure of the patient; G is the cortisol of the patient; H is the renin activity of the patient.

[0053] The determination module includes:

[0054] The first determination unit is used to determine that the possibility of complete clinical remission after the operation of the patient is less than 20% when the prognostic evaluation score is: S > -1.510;

[0055] The second determination unit is used to determine that the possibility of complete clinical remission after the operation of the patient is 73% when the prognostic evaluation score is: -1.163 < S ≤ -1.510;

[0056] The third determination unit is used to determine that the possibility of complete clinical remission after the operation of the patient is 75% when the prognostic evaluation score is: -0.462 < S ≤ -1.163;

[0057] The fourth determination unit is used to determine that the possibility of complete clinical remission after the operation of the patient is 80% when the prognostic evaluation score is: -0.462 < S ≤ -0.207;

[0058] The fifth determination unit is used to determine that the possibility of complete clinical remission after the operation of the patient is 90% when the prognostic evaluation score is: S < -0.207.

[0059] The third embodiment of the present invention relates to a computer-readable storage medium, on which a computer program is stored. When the computer program is executed by a processor, the steps of the prognostic evaluation method for patients with primary aldosteronism in the first embodiment are realized.

[0060] Those skilled in the art will appreciate that the embodiments of the present application may be provided as methods, systems, or computer program products. Therefore, the present application may adopt the form of a complete hardware embodiment, a complete software embodiment, or an embodiment in combination with software and hardware. Moreover, the present application may adopt the form of a computer program product implemented on one or more computer-usable storage media (including but not limited to disk storage and optical storage, etc.) that contain computer-usable program code.

[0061] The present application is described with reference to the flowcharts and / or block diagrams of the methods, devices (systems), and computer program products according to the embodiments of the present application. It should be understood that each process and / or box in the flowchart and / or block diagram, as well as the combination of the processes and / or boxes in the flowchart and / or block diagram, can be implemented by computer program instructions. These computer program instructions can be provided to a processor of a general-purpose computer, a special-purpose computer, an embedded processor, or other programmable data processing device to generate a machine, so that the instructions executed by the processor of the computer or other programmable data processing device generate instructions for implementing the processes in the flowchart and / or block diagram. Figure 1 A process or multiple processes and / or boxes Figure 1 A device that provides the functions specified in a block or multiple blocks.

[0062] These computer program instructions may also be stored in a computer-readable memory that can direct a computer or other programmable data processing device to work in a specific manner, so that the instructions stored in the computer-readable memory produce a manufactured product including an instruction method, which is implemented in the process Figure 1 A process or multiple processes and / or boxes Figure 1 A function specified in one or more boxes.

[0063] These computer program instructions can also be loaded onto a computer or other programmable data processing device so that a series of operating steps are executed on the computer or other programmable device to produce a computer-implemented process, thereby providing instructions for implementing the process. Figure 1 A process or multiple processes and / or boxes Figure 1 The steps for the functions specified in one or more boxes.

[0064] The above is only a specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Any person skilled in the art can easily think of changes or substitutions within the technical scope disclosed by the present invention, which should be included in the protection scope of the present invention. Therefore, the protection scope of the present invention should be based on the protection scope of the claims.

Claims

1. A method for evaluating the prognosis of patients with primary aldosteronism, characterized in that: It includes the following steps: Obtain the basic information of the patient; Measure the blood pressure information of the patient to obtain the systolic blood pressure of the patient; Collect the blood sample of the patient and determine the value of the prognostic indication parameter from the blood sample of the patient; Use the basic information, systolic blood pressure and prognostic indication parameter value of the patient as the input of the prognostic evaluation model to obtain the prognostic evaluation score; Determine the prognostic evaluation result of the patient according to the interval where the prognostic evaluation score is located.

2. The method for evaluating the prognosis of a patient with primary aldosteronism according to claim 1, wherein: Before collecting the blood sample of the patient, the mineralocorticoid receptor antagonist and non-potassium-sparing diuretic need to be discontinued for 4 weeks, and the β-blocker, angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker need to be discontinued for 2 weeks; replace the antihypertensive drug with a non-dihydropyridine calcium blocker and / or α-blocker.

3. The method for evaluating the prognosis of a patient with primary aldosteronism according to claim 1, wherein: When collecting the blood sample of the patient, the patient needs to maintain an upright posture within the first preset duration, sit down after the first preset duration and continue for the second preset duration, and collect the blood sample after the second preset duration; the time period for collecting the blood sample is in the morning; among them, the first preset duration is 8 times the second preset duration.

4. The method for evaluating the prognosis of a patient with primary aldosteronism according to claim 1, wherein: The basic information of the patient includes: age, gender, KCNJ5 gene mutation, hypertension course and body mass index; the value of the prognostic indication parameter includes: cortisol and renin activity.

5. The method for evaluating the prognosis of a patient with primary aldosteronism according to claim 4, characterized in that: The prognostic evaluation model is: Among them, S is the prognostic evaluation score, A is the patient's age, B represents the patient's gender, when the gender is male, B = 1, when the gender is female, B = 2; C is the KCNJ5 gene mutation, when the KCNJ5 gene has a mutation, C = 2, when the KCNJ5 gene has no mutation, C = 1; D is the course of hypertension; E is the patient's body mass index; F is the patient's systolic blood pressure; G is the cortisol of the patient; H is the renin activity of the patient.

6. The method for evaluating the prognosis of a patient with primary aldosteronism according to claim 1, wherein: Determine the prognostic evaluation result of the patient according to the interval where the prognostic evaluation score is located, specifically: When the prognostic evaluation score is: S > -1.510, the possibility of complete clinical remission after the patient's surgery is less than 20%; When the prognostic evaluation score is: -1.163 < S ≤ -1.510, the possibility of complete clinical remission after the patient's surgery is 73%; When the prognostic evaluation score is: -0.462 < S ≤ -1.163, the possibility of complete clinical remission after the patient's surgery is 75%; When the prognostic evaluation score is: -0.462 < S ≤ -0.207, the possibility of complete clinical remission after the patient's surgery is 80%; When the prognostic evaluation score is: S < -0.207, the possibility of complete clinical remission after the patient's surgery is 90%; Among them, S is the prognostic evaluation score.

7. A device for assessing the prognosis of patients with primary aldosteronism, characterized in that: It includes: An acquisition module for obtaining the basic information of the patient; A blood pressure measurement module for measuring the blood pressure information of the patient to obtain the systolic blood pressure of the patient; A blood sample collection module for collecting the blood sample of the patient and determining the value of the prognostic indication parameter from the blood sample of the patient; An evaluation module for using the basic information, systolic blood pressure and prognostic indication parameter value of the patient as the input of the prognostic evaluation model to obtain the prognostic evaluation score; A determination module for determining the prognostic evaluation result of the patient according to the interval where the prognostic evaluation score is located.

8. The device for evaluating the prognosis of patients with primary aldosteronism according to claim 7, characterized in that: The basic information of the patient includes: age, gender, KCNJ5 gene mutation, hypertension course and body mass index; the value of the prognostic indication parameter includes: cortisol and renin activity.

9. The device for evaluating the prognosis of a patient with primary aldosteronism according to claim 7, characterized in that: The prognostic evaluation model is: Among them, S is the prognostic evaluation score, A is the patient's age, B represents the patient's gender, when the gender is male, B = 1, when the gender is female, B = 2; C is the KCNJ5 gene mutation, when the KCNJ5 gene has a mutation, C = 2, when the KCNJ5 gene has no mutation, C = 1; D is the course of hypertension; E is the patient's body mass index; F is the patient's systolic blood pressure; G is the cortisol of the patient; H is the renin activity of the patient.

10. A computer-readable storage medium having a computer program stored thereon, characterized in that: When the computer program is executed by a processor, it implements the steps of the method for prognostic evaluation of patients with primary aldosteronism as described in any one of claims 1-6.

Images